IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0707037
(2010-02-17)
|
등록번호 |
US-8492124
(2013-07-23)
|
발명자
/ 주소 |
- Ritter, Andrew J.
- Savaiano, Dennis
- Barnes, David
- Klaenhammer, Todd Robert
|
출원인 / 주소 |
- Ritter Pharmaceuticals, Inc.
|
대리인 / 주소 |
Wilson Sonsini Goodrich & Rosati
|
인용정보 |
피인용 횟수 :
5 인용 특허 :
102 |
초록
▼
The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolera
The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes.
대표청구항
▼
1. A method for treating lactose intolerance in a subject who has experienced one or more symptoms of lactose intolerance, said method comprising administering a pharmaceutical composition comprising galactooligosaccharides (GOS) to said subject for a predetermined number of days, wherein after said
1. A method for treating lactose intolerance in a subject who has experienced one or more symptoms of lactose intolerance, said method comprising administering a pharmaceutical composition comprising galactooligosaccharides (GOS) to said subject for a predetermined number of days, wherein after said administering said subject experiences a reduction of at least one of said one or more symptoms of lactose intolerance, wherein said pharmaceutical composition is formulated for controlled release, comprises an enteric coating, or is provided in a dosage form that is a capsule, tablet, softgel, powder, effervescent form, or lozenge, and wherein said pharmaceutical composition does not contain a probiotic. 2. The method of claim 1, wherein said subject experiences said reduction of at least one of said one or more symptoms of lactose intolerance after consumption of an amount of lactose that previously caused said one or more symptoms of lactose intolerance. 3. The method of claim 1, wherein said method comprises administering a lower dosage of GOS on the first day of administration than the last day of administration. 4. The method of claim 1, wherein said method comprises administering the same dosage of GOS on the first day of administration as the last day of administration. 5. The method of claim 1, wherein said method comprises administering said pharmaceutical composition once a day. 6. The method of claim 1, wherein said method comprises administering said pharmaceutical composition twice a day. 7. The method of claim 1, wherein said method comprises administering said pharmaceutical composition three times a day. 8. The method of claim 1, wherein said pharmaceutical composition comprising GOS is administered without a meal. 9. The method of claim 1, wherein said pharmaceutical composition comprising GOS is administered in conjunction with a meal. 10. The method of claim 9, wherein said pharmaceutical composition comprising GOS is administered with breakfast and dinner. 11. The method of claim 9, wherein said pharmaceutical composition comprising GOS is administered with breakfast, lunch, and dinner. 12. The method of claim 1, wherein said one or more symptoms comprise heartburn, stomach upset, nausea, bloating, flatulence, diarrhea, abdominal pain, cramping, or vomiting. 13. The method of claim 1, wherein at least 96% of the total weight of said pharmaceutical composition is GOS. 14. The method of claim 1, wherein at least 40% of the total weight of said pharmaceutical composition is GOS. 15. The method of claim 1, wherein at least 60% of the total weight of said pharmaceutical composition is GOS. 16. The method of claim 1, wherein at least 80% of the total weight of said pharmaceutical composition is GOS. 17. The method of claim 1, wherein at least 95% of the total weight of said pharmaceutical composition is GOS. 18. The method of claim 1, wherein said predetermined number of days is 5 to 40 days. 19. The method of claim 1, further comprising diagnosing said subject as having lactose intolerance prior to said administering said pharmaceutical composition comprising GOS.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.